VGXI, a plasmid DNA contract manufacturer, celebrated the official grand opening and ribbon cutting for its new headquarters and manufacturing facility located in Conroe, TX on Friday, October 7, 2022.
VGXI Celebrates the Grand Opening for its New Headquarters and Manufacturing Facility
An Introduction to DNA and Vaccines
Vaccines are one of humanity’s most important inventions as they help protect public health and save millions of lives every year. By stimulating the body’s immune system to elicit an immune response, vaccines have protected people from deadly diseases such as smallpox, rinderpest, and malaria, among others. Traditionally, vaccines are made from weak or inactivated… Read More »
VGXI Announces Grand Opening Celebration for New Headquarters and Manufacturing Facility
Specialized plasmid DNA contract manufacturer VGXI, Inc. announces date for the Grand Opening celebration of its new headquarters and expanded manufacturing facility in Conroe, TX. VGXI, Inc., an industry-leading contract developer and manufacturer (CDMO) of nucleic acid biopharmaceuticals including gene therapies, DNA vaccines, and RNA medicines, announces the official Grand Opening celebration for its new… Read More »
VGXI Celebrates First Look Event at New Manufacturing Facility
VGXI opened the doors of its new headquarters and manufacturing facility on 09Apr22 to provide friends and employee families a first look inside and outside the new site! As production is nearing completion, the event was an opportunity for employees and their families to tour the production suites, labs, and office spaces before the official… Read More »
VGXI Official COVID-19 Statement
To our Valued Clients and Business Partners, VGXI’s top priority is to continue delivering the highest quality DNA products and services while ensuring the security and safety of our team. VGXI is actively monitoring the evolving situation and will continue to provide updates as new information becomes available. Manufacturing activities have been maintained throughout the… Read More »
VGXI Partner IMM Announces $12M NIH Grant to Support Phase 1 Clinical Trial of a DNA Vaccine for the Prevention of Alzheimer’s Disease
Texas-based CDMO VGXI, Inc. is excited to announce that its partner, The Institute for Molecular Medicine, has recently been awarded a $12 million NIA grant to support clinical testing of a novel DNA vaccine manufactured by VGXI for the prevention of Alzheimer’s Disease. The Woodlands, TX – VGXI, Inc., an industry recognized contract developer and… Read More »